stockportfolio.pro
Stocks / A vs ALNY
A vs ALNY
Agilent Technologies, Inc. and Alnylam Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Agilent Technologies, Inc. (A) | Alnylam Pharmaceuticals, Inc. (ALNY) | |
|---|---|---|
| Market cap | $38.3B | $38.9B |
| Revenue (latest FY) | $6.95B | $3.71B |
| Net income (latest FY) | $1.30B | $313.75M |
| Revenue growth (5y CAGR) | 5.4% | 49.8% |
| Net margin | 18.8% | 8.4% |
| Return on equity | 19.3% | 39.8% |
| P/E ratio | 26.7 | 73.0 |
| Dividend yield | 0.8% | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open A — free Open ALNY — freeFrequently asked questions
Which is bigger, A or ALNY?
Alnylam Pharmaceuticals, Inc. is larger by market capitalization — $38.9B versus $38.3B.
Which grows faster, A or ALNY?
Over the last five fiscal years, Alnylam Pharmaceuticals, Inc. grew revenue faster — 49.8%/yr versus 5.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.